You are here

Hemgenix

After Hemgenix approvals, uniQure cashes out some of its royalty rights for $375M-plus

After Hemgenix approvals, uniQure cashes out some of its royalty rights for $375M-plus

Fierce Pharma

Flag link:

First Gene Therapy for Hemophilia B, CSL's HEMGENIX®, Approved by the European Commission

First Gene Therapy for Hemophilia B, CSL's HEMGENIX®, Approved by the European Commission

BioSpace

Flag link:

Despite Eye-Popping $3.5 Million Price Tag For Gene Therapy Hemgenix, Budget Impact For Most Payers Will Be Relatively Small

Despite Eye-Popping $3.5 Million Price Tag For Gene Therapy Hemgenix, Budget Impact For Most Payers Will Be Relatively Small

Forbes

Flag link:

A $3.5M ‘bargain’? CSL’s hemophilia B drug sets new pricing benchmark, as gene therapy costs mount

A $3.5M ‘bargain’? CSL’s hemophilia B drug sets new pricing benchmark, as gene therapy costs mount

Medical Marketing and Media

Flag link:

uniQure, CSL claim first okay for hemophilia B gene therapy

uniQure, CSL claim first okay for hemophilia B gene therapy

Pharmaphorum

Flag link: